<li>aceclofenac<p>aceclofenac decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>acemetacin<p>acemetacin decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>agrimony<p>agrimony increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>albuterol<p>albuterol, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>arformoterol<p>arformoterol, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>aspirin<p>aspirin decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>aspirin rectal<p>aspirin rectal decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>bambuterol<p>bambuterol, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>birch<p>birch increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>bitter melon<p>bitter melon, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>brimonidine<p>brimonidine increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>budesonide<p>budesonide, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>calcium acetate<p>furosemide decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>calcium carbonate<p>furosemide decreases levels of calcium carbonate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>calcium chloride<p>furosemide decreases levels of calcium chloride by increasing renal clearance. Minor/Significance Unknown.</p></li><li>calcium citrate<p>furosemide decreases levels of calcium citrate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>calcium gluconate<p>furosemide decreases levels of calcium gluconate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>carbenoxolone<p>furosemide, carbenoxolone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive hypokalemic effects.</p></li><li>cefaclor<p>cefaclor increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>cefadroxil<p>cefadroxil increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>cefamandole<p>cefamandole increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>cefazolin<p>cefazolin increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>cefdinir<p>cefdinir increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>cefditoren<p>cefditoren increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>cefepime<p>cefepime increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>cefixime<p>cefixime increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>cefotetan<p>cefotetan increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>cefoxitin<p>cefoxitin increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>cefpirome<p>cefpirome increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>cefpodoxime<p>cefpodoxime increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>cefprozil<p>cefprozil increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>ceftazidime<p>ceftazidime increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>ceftibuten<p>ceftibuten increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>ceftizoxime<p>ceftizoxime increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>ceftriaxone<p>ceftriaxone increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>cefuroxime<p>cefuroxime increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>celecoxib<p>celecoxib decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>cephalexin<p>cephalexin increases toxicity of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Increased risk of nephrotoxicity.</p></li><li>cephaloridine<p>furosemide, cephaloridine.
Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive nephrotoxicity.</p></li><li>choline magnesium trisalicylate<p>choline magnesium trisalicylate decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>clobetasone<p>clobetasone, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>colestipol<p>colestipol decreases levels of furosemide by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>corticotropin<p>corticotropin, furosemide. pharmacodynamic synergism. Minor/Significance Unknown. Possible enhanced electrolyte loss.</p></li><li>cortisone<p>cortisone, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>cosyntropin<p>cosyntropin, furosemide. pharmacodynamic synergism. Minor/Significance Unknown. Possible enhanced electrolyte loss.</p></li><li>deflazacort<p>deflazacort, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>dexamethasone<p>dexamethasone, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>diclofenac<p>diclofenac decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>diflunisal<p>diflunisal decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>dobutamine<p>dobutamine, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>dopexamine<p>dopexamine, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>duloxetine<p>furosemide, duloxetine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>ephedrine<p>ephedrine, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>ephedrine (pulmonary)<p>ephedrine (pulmonary), furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>epinephrine<p>epinephrine, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>epinephrine racemic<p>epinephrine racemic, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>epoprostenol<p>epoprostenol increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects.</p></li><li>escitalopram<p>furosemide, escitalopram. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>ethotoin<p>ethotoin decreases levels of furosemide by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>etodolac<p>etodolac decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>etoricoxib<p>etoricoxib decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>fenbufen<p>fenbufen decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>fenoprofen<p>fenoprofen decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>fludrocortisone<p>fludrocortisone, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>fluoxetine<p>furosemide, fluoxetine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>flurbiprofen<p>flurbiprofen decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>fluvoxamine<p>furosemide, fluvoxamine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>fo-ti<p>fo-ti increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).</p></li><li>folic acid<p>furosemide decreases levels of folic acid by increasing renal clearance. Minor/Significance Unknown.</p></li><li>formoterol<p>formoterol, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>forskolin<p>forskolin increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>fosphenytoin<p>fosphenytoin decreases levels of furosemide by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>germanium<p>germanium decreases effects of furosemide by unknown mechanism. Minor/Significance Unknown. Case report.</p></li><li>goldenrod<p>goldenrod increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>hydrocortisone<p>hydrocortisone, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>ibuprofen<p>ibuprofen decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>indomethacin<p>indomethacin decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>isoproterenol<p>isoproterenol, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>ketoprofen<p>ketoprofen decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>ketorolac<p>ketorolac decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>ketorolac intranasal<p>ketorolac intranasal decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>l-methylfolate<p>furosemide decreases levels of l-methylfolate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>levalbuterol<p>levalbuterol, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>levomilnacipran<p>furosemide, levomilnacipran. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>levothyroxine<p>furosemide increases toxicity of levothyroxine by Other (see comment). Minor/Significance Unknown. 
Comment: High doses (greater than 80 mg) of furosemide may inhibit binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by overall decrease in total thyroid hormone levels.</p></li><li>liothyronine<p>furosemide increases toxicity of liothyronine by Other (see comment). Minor/Significance Unknown. 
Comment: High doses (greater than 80 mg) of furosemide may inhibit binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by overall decrease in total thyroid hormone levels.</p></li><li>liotrix<p>furosemide increases toxicity of liotrix by Other (see comment). Minor/Significance Unknown. 
Comment: High doses (greater than 80 mg) of furosemide may inhibit binding of thyroid hormones to carrier proteins and result in transient increase in free thyroid hormones, followed by overall decrease in total thyroid hormone levels.</p></li><li>lofexidine<p>lofexidine increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>lornoxicam<p>lornoxicam decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>magnesium chloride<p>furosemide decreases levels of magnesium chloride by increasing renal clearance. Minor/Significance Unknown.</p></li><li>magnesium citrate<p>furosemide decreases levels of magnesium citrate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>magnesium hydroxide<p>furosemide decreases levels of magnesium hydroxide by increasing renal clearance. Minor/Significance Unknown.</p></li><li>magnesium oxide<p>furosemide decreases levels of magnesium oxide by increasing renal clearance. Minor/Significance Unknown.</p></li><li>magnesium sulfate<p>furosemide decreases levels of magnesium sulfate by increasing renal clearance. Minor/Significance Unknown.</p></li><li>meclofenamate<p>meclofenamate decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>mefenamic acid<p>mefenamic acid decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>meloxicam<p>meloxicam decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>metaproterenol<p>metaproterenol, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>metformin<p>metformin decreases levels of furosemide by unspecified interaction mechanism. Minor/Significance Unknown.<span><br><br></span>furosemide increases levels of metformin by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>methylprednisolone<p>methylprednisolone, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>milnacipran<p>furosemide, milnacipran. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>minoxidil<p>furosemide increases effects of minoxidil by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>nabumetone<p>nabumetone decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>naproxen<p>naproxen decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>nefazodone<p>furosemide, nefazodone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>noni juice<p>noni juice increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Minor/Significance Unknown.</p></li><li>norepinephrine<p>norepinephrine, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>octacosanol<p>octacosanol increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>oxaprozin<p>oxaprozin decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>parecoxib<p>parecoxib decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>paroxetine<p>furosemide, paroxetine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>penicillin g aqueous<p>furosemide increases levels of penicillin g aqueous by decreasing renal clearance. Minor/Significance Unknown.</p></li><li>penicillin vk<p>furosemide increases levels of penicillin vk by decreasing renal clearance. Minor/Significance Unknown.</p></li><li>phenobarbital<p>phenobarbital decreases levels of furosemide by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>phenytoin<p>phenytoin decreases levels of furosemide by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>pirbuterol<p>pirbuterol, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>piroxicam<p>piroxicam decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>prednisolone<p>prednisolone, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>prednisone<p>prednisone, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>reishi<p>reishi increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>salicylates (non-asa)<p>salicylates (non-asa) decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>salmeterol<p>salmeterol, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.</p></li><li>salsalate<p>salsalate decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>sertraline<p>furosemide, sertraline. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>shepherd's purse<p>shepherd's purse, furosemide. Other (see comment). Minor/Significance Unknown. 
Comment: Theoretically, shepherd's purse may interfere with BP control.</p></li><li>sulfadiazine<p>furosemide increases levels of sulfadiazine by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>sulfamethoxazole<p>furosemide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>sulfasalazine<p>sulfasalazine decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>sulfisoxazole<p>furosemide increases levels of sulfisoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>sulindac<p>sulindac decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>terbutaline<p>terbutaline, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Hypokalemia.<span><br><br></span>furosemide, terbutaline. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive hypokalemic effects.</p></li><li>thiamine<p>furosemide decreases levels of thiamine by increasing renal clearance. Minor/Significance Unknown.</p></li><li>tizanidine<p>tizanidine increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension.</p></li><li>tolfenamic acid<p>tolfenamic acid decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>tolmetin<p>tolmetin decreases effects of furosemide by pharmacodynamic antagonism. Minor/Significance Unknown. NSAIDs decrease prostaglandin synthesis.</p></li><li>trazodone<p>furosemide, trazodone. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>treprostinil<p>treprostinil increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>triamcinolone<p>triamcinolone, furosemide. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia, especially with strong glucocorticoid activity.</p></li><li>tubocurarine<p>furosemide increases effects of tubocurarine by unknown mechanism. Minor/Significance Unknown.</p></li><li>venlafaxine<p>furosemide, venlafaxine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Possible additive hyponatremia.</p></li><li>zoledronic acid<p>furosemide, zoledronic acid. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive hypocalcemia.</p></li>